September 22nd, 2026Tebentafusp Sustains Survival Benefit at 5 Years in Metastatic Uveal Melanoma Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma. Read more